Modalis Therapeutics Corporation (4883)

Overview

Modalis Therapeutics Corporation, initially established as EdiGENE Corporation before rebranding in August 2019, is a Tokyo-based biotechnology firm founded in 2016. The company is at the forefront of developing innovative therapeutic solutions for patients afflicted with severe genetic disorders. It harnesses the potential of its proprietary CRISPR-GNDM technology, which provides a unique approach to modulate gene expressions by targeting the epigenetics of specific loci. In its pursuit of breakthroughs in genetic treatments, Modalis Therapeutics has entered into a strategic joint research agreement with JCR Pharmaceuticals Co., Ltd. This collaboration focuses on advancing the drug delivery mechanisms of gene therapies to the central nervous system (CNS), with a particular emphasis on treating CNS diseases.

Products and Services

• CRISPR-GNDM Technology

  This advanced technological platform stands at the core of Modalis Therapeutics' research and development efforts. The CRISPR-GNDM (CRISPR-Gene Normalization Drug Modality) technology empowers scientists to precisely modulate gene expression. It aims at the epigenetic level of specific genomic loci, offering a promising route to rectify genetic anomalies that underpin various disorders. Through this technology, Modalis strives to create therapies that can control or cure serious genetic conditions, making significant strides in the realm of personalized medicine.

• Joint Research on CNS Drug Delivery

  In collaboration with JCR Pharmaceuticals Co., Ltd., Modalis Therapeutics is exploring innovative approaches to enhance the effectiveness of gene therapies for the central nervous system. This joint research effort aims to overcome the significant challenge of delivering therapeutic agents across the blood-brain barrier, a major obstacle in treating CNS diseases. The partnership leverages both companies' expertise to develop delivery technologies that could potentially transform the treatment landscape for a myriad of central nervous system disorders, indicating a promising direction for future therapeutic strategies.